The Compound on $IQV (Oct 27, 2026)
He does not like IQVIA's chart shape and does not see the bull case, given many competing vendors in its contract-research business; even if IQV fills the July gap at 213 within six months, he would not invest in it.
Jump to any passage
Good. the next. We wrote about this stock last week. This is IQVIA. I guarantee you that none of you have ever heard of it before. I have never heard of any of these names. I mean, I've heard of it.
I don't know what these stocks are. The goal of this exercise that Shawn and I are doing. We want people to learn about stocks they've never heard of before. No, I'm almost certain I'm the only person who mentioned this stock on CNBC.
This company has been operating since 1954. I don't like, I don't like the shape of this stock. There are many, many vendors here. I don't see what you see . It is a contract research organization for pharmaceutical companies.
They help pharmaceutical companies develop drugs using data. They may possess the most important private pharmaceutical data library on Earth. Well, this will close the gap, the July gap at 213, over the next six months.
Keep that in mind. I won't be there, I won't invest in it if that happens. You can see where the obvious stopping point is at the gap, can't you ?